{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:32:56Z","timestamp":1790757176109,"version":"4.1.0"},"reference-count":217,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"DOI":"10.3389\/fcell.2019.00207","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T03:49:34Z","timestamp":1570765774000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects"],"prefix":"10.3389","volume":"7","author":[{"given":"Valentina","family":"Gambacorta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Vago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Di Micco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1172\/JCI89364","article-title":"Versatile humanized niche model enables study of normal and malignant human hematopoiesis.","volume":"127","author":"Abarrategi","year":"2017","journal-title":"J. Clin. Invest."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1474","article-title":"Aging human hematopoietic stem cells manifest profound epigenetic reprogramming of enhancers that may predispose to leukemia.","author":"Adelman","year":"2019","journal-title":"Cancer Discov."},{"key":"B3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.leukres.2010.02.004","article-title":"The DNA demethylating agent 5-aza-2\u2019-deoxycytidine induces expression of NY-ESO-1 and other cancer\/testis antigens in myeloid leukemia cells.","volume":"34","author":"Almstedt","year":"2010","journal-title":"Leuk. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.cell.2004.05.009","article-title":"Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53.","volume":"117","author":"An","year":"2004","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1182\/blood-2016-05-719021","article-title":"Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.","volume":"128","author":"Antonelli","year":"2016","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature13229","article-title":"Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.","volume":"510","author":"Asangani","year":"2014","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nature25193","article-title":"A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies.","volume":"553","author":"Bahr","year":"2018","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"32646","DOI":"10.18632\/oncotarget.5066","article-title":"Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.","volume":"6","author":"Baker","year":"2015","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.","volume":"280","author":"Bali","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.00178","article-title":"HERVs new role in cancer: from accused perpetrators to cheerful protectors.","volume":"9","author":"Bannert","year":"2018","journal-title":"Front. Microbiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1084\/jem.20181276","article-title":"Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.","volume":"216","author":"Basheer","year":"2019","journal-title":"J. Exp. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1182\/blood-2012-01-406116","article-title":"Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia.","volume":"119","author":"Beekman","year":"2012","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","article-title":"MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.","volume":"20","author":"Bernt","year":"2011","journal-title":"Cancer Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1182\/blood-2017-08-804344","article-title":"Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas.","volume":"131","author":"Bisserier","year":"2018","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.celrep.2014.08.025","article-title":"Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition.","volume":"8","author":"Bolden","year":"2014","journal-title":"Cell Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/ng0996-33","article-title":"The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein.","volume":"14","author":"Borrow","year":"1996","journal-title":"Nat. Genet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/leu.2010.20","article-title":"Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/ng.3889","article-title":"DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats.","volume":"49","author":"Brocks","year":"2017","journal-title":"Nat. Genet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/leu.2017.339","article-title":"SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.","volume":"32","author":"Bu","year":"2018","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1038\/leu.2017.242","article-title":"Phase I\/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial).","volume":"31","author":"Bug","year":"2017","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.1074\/jbc.M110.202416","article-title":"Protein-arginine methyltransferase 1 (PRMT1) methylates Ash2L, a shared component of mammalian histone H3K4 methyltransferase complexes.","volume":"286","author":"Butler","year":"2011","journal-title":"J. Biol. Chem."},{"key":"B23","first-page":"55","article-title":"Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.","volume":"58","author":"Caligiuri","year":"1998","journal-title":"Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1038\/onc.2008.273","article-title":"HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance.","volume":"27","author":"Campoli","year":"2008","journal-title":"Oncogene"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.","volume":"368","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.molcel.2013.12.001","article-title":"Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.","volume":"53","author":"Cao","year":"2014","journal-title":"Mol. Cell."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.02482","article-title":"SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint.","volume":"3","author":"Carvalho","year":"2014","journal-title":"eLife"},{"key":"B28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.","volume":"28","author":"Cashen","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/ng.1009","article-title":"Dnmt3a is essential for hematopoietic stem cell differentiation.","volume":"44","author":"Challen","year":"2011","journal-title":"Nat. Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.","volume":"11","author":"Chan-Penebre","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1182\/blood-2013-03-491571","article-title":"Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.","volume":"122","author":"Chaturvedi","year":"2013","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/leu.2012.327","article-title":"Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.","volume":"27","author":"Chen","year":"2013","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ccell.2015.12.007","article-title":"Targeting aberrant epigenetic networks mediated by PRMT1 and KDM4C in acute myeloid leukemia.","volume":"29","author":"Cheung","year":"2016","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses.","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2010-05-283291","article-title":"Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations.","volume":"116","author":"Chou","year":"2010","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/sj.leu.2404623","article-title":"Expression of polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia.","volume":"21","author":"Chowdhury","year":"2007","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation.","volume":"379","author":"Christopher","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.032","article-title":"Restoration of TET2 function blocks aberrant self-renewal and leukemia progression.","volume":"170","author":"Cimmino","year":"2017","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.bbrc.2016.05.010","article-title":"Hydroquinone induces DNA hypomethylation-independent overexpression of retroelements in human leukemia and hematopoietic stem cells.","volume":"474","author":"Conti","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00262-012-1365-1367","article-title":"Immunomodulatory activity of SGI-110, a 5-aza-2\u2019-deoxycytidine-containing demethylating dinucleotide.","volume":"62","author":"Coral","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/00002371-199901000-00003","article-title":"Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2\u2019-deoxycytidine (5-AZA-CdR).","volume":"22","author":"Coral","year":"1999","journal-title":"J. Immunother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/ng.3646","article-title":"Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution.","volume":"48","author":"Corces","year":"2016","journal-title":"Nat. Genet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"17698","DOI":"10.18632\/oncotarget.4131","article-title":"BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.","volume":"6","author":"Coude","year":"2015","journal-title":"Oncotarget"},{"key":"B45","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","article-title":"Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial.","volume":"22","author":"Craddock","year":"","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B46","doi-asserted-by":"publisher","first-page":"879","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.","volume":"101","author":"Craddock","year":"","journal-title":"Haematologica"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/15384101.2018.1442623","article-title":"Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors.","volume":"17","author":"Daskalakis","year":"2018","journal-title":"Cell Cycle"},{"key":"B50","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study.","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"key":"B51","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.","volume":"116","author":"de Lima","year":"2010","journal-title":"Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1038\/leu.2013.38","article-title":"Phase Ia\/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.","volume":"27","author":"DeAngelo","year":"2013","journal-title":"Leukemia"},{"key":"B54","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nsmb.3228","article-title":"BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin.","volume":"23","author":"Devaiah","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018100293","article-title":"BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses.","volume":"38","author":"Dey","year":"2019","journal-title":"EMBO J."},{"key":"B56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.celrep.2014.08.055","article-title":"Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes.","volume":"9","author":"Di Micco","year":"2014","journal-title":"Cell Rep."},{"key":"B57","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/ncb2170","article-title":"Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer.","volume":"13","author":"Di Micco","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1021\/cb300024c","article-title":"Novel inhibitors for PRMT1 discovered by high-throughput screening using activity-based fluorescence polarization.","volume":"7","author":"Dillon","year":"2012","journal-title":"ACS Chem Biol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML.","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia.","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1200\/JCO.2002.09.088","article-title":"Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the acute myeloid leukemia study group ulm.","volume":"20","author":"Dohner","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"B63","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1158\/2159-8290.CD-19-0106","article-title":"Rational targeting of cooperating layers of the epigenome yields enhanced therapeutic efficacy against AML.","volume":"9","author":"Duy","year":"2019","journal-title":"Cancer Discov."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition.","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov."},{"key":"B65","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"B66","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cell.2014.07.031","article-title":"Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus.","volume":"158","author":"Feng","year":"2014","journal-title":"Cell"},{"key":"B67","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.","volume":"18","author":"Figueroa","year":"","journal-title":"Cancer Cell"},{"key":"B68","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia.","volume":"17","author":"Figueroa","year":"","journal-title":"Cancer Cell"},{"key":"B69","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation.","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"B70","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/bjh.12332","article-title":"A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy.","volume":"161","author":"Finazzi","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/leu.2014.119","article-title":"Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.","volume":"28","author":"Fiskus","year":"2014","journal-title":"Leukemia"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2017.11.004","article-title":"Harnessing BET inhibitor sensitivity reveals AMIGO2 as a melanoma survival gene.","volume":"68","author":"Fontanals-Cirera","year":"2017","journal-title":"Mol. Cell."},{"key":"B73","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/leu.2017.300","article-title":"Dual inhibition of EZH1\/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.","volume":"32","author":"Fujita","year":"2018","journal-title":"Leukemia"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055481","article-title":"A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.","volume":"8","author":"Gao","year":"2013","journal-title":"PLoS One"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(19)30029-30028","article-title":"Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1\/2 trial.","volume":"6","author":"Garcia-Manero","year":"2019","journal-title":"Lancet Haematol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1200\/JCO.2011.38.3265","article-title":"Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.","volume":"30","author":"Garcia-Manero","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11899-017-0363-364","article-title":"Hypomethylating agents as a therapy for AML.","volume":"12","author":"Gardin","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B79","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1158\/1541-7786.MCR-06-0111","article-title":"Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?","volume":"4","author":"Gaymes","year":"2006","journal-title":"Mol. Cancer Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1038\/s41388-018-0150-152","article-title":"The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.","volume":"37","author":"Gerlach","year":"2018","journal-title":"Oncogene"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2016.07.010","article-title":"Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.","volume":"49","author":"Ghobadi","year":"2016","journal-title":"Leuk. Res."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation.","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"B83","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/onc.2015.114","article-title":"Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.","volume":"35","author":"Gibaja","year":"2016","journal-title":"Oncogene"},{"key":"B84","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1158\/1078-0432.CCR-06-0511","article-title":"A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.","volume":"12","author":"Giles","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/2159-8290.CD-16-1032","article-title":"Epigenetic identity in AML depends on disruption of nonpromoter regulatory elements and is affected by antagonistic effects of mutations in epigenetic modifiers.","volume":"7","author":"Glass","year":"2017","journal-title":"Cancer Discov."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1158\/1078-0432.CCR-12-3165","article-title":"Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.","volume":"19","author":"Gojo","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.","volume":"20","author":"Gottlicher","year":"2001","journal-title":"EMBO J."},{"key":"B90","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1600-0609.2008.01083.x","article-title":"Gene expression profiling of polycomb, hox and meis genes in patients with acute myeloid leukaemia.","volume":"81","author":"Grubach","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0208-203","article-title":"Model-based adaptive phase i trial design of post-transplant decitabine maintenance in myelodysplastic syndrome.","volume":"8","author":"Han","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1021\/jm401868d","article-title":"High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein\u2014protein interaction.","volume":"57","author":"He","year":"2014","journal-title":"J. Med. Chem."},{"key":"B94","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1038\/sj.onc.1207674","article-title":"ETO interacting proteins.","volume":"23","author":"Hug","year":"2004","journal-title":"Oncogene"},{"key":"B95","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1101\/gad.447007","article-title":"PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation.","volume":"21","author":"Hyllus","year":"2007","journal-title":"Genes Dev."},{"key":"B96","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1074\/jbc.C700192200","article-title":"Arginine methylation of the histone H3 tail impedes effector binding.","volume":"283","author":"Iberg","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B97","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nm1160","article-title":"Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway.","volume":"11","author":"Insinga","year":"2005","journal-title":"Nat. Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-38","article-title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.","volume":"16","author":"Issa","year":"2015","journal-title":"Lancet Oncol."},{"key":"B99","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood.V97.9.2815","article-title":"The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling.","volume":"97","author":"Izutsu","year":"2001","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1182\/blood-2010-12-327668","article-title":"Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.","volume":"117","author":"Jo","year":"2011","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/leu.2017.206","article-title":"Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.","volume":"32","author":"Kaushik","year":"2018","journal-title":"Leukemia"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1084\/jem.20070109","article-title":"CREB\/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation.","volume":"204","author":"Kim","year":"2007","journal-title":"J. Exp. Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.13016","article-title":"A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.","volume":"167","author":"Kirschbaum","year":"2014","journal-title":"Br. J. Haematol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/sj.leu.2401983","article-title":"Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation.","volume":"15","author":"Kitabayashi","year":"2001","journal-title":"Leukemia"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.3324\/haematol.2014.115337","article-title":"MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.","volume":"100","author":"Kuhn","year":"2015","journal-title":"Haematologica"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.celrep.2016.06.091","article-title":"Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer.","volume":"16","author":"Kurimchak","year":"2016","journal-title":"Cell Rep."},{"key":"B108","doi-asserted-by":"publisher","first-page":"259","DOI":"10.4049\/jimmunol.182.1.259","article-title":"Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation.","volume":"182","author":"Lal","year":"2009","journal-title":"J. Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1101\/gad.236794.113","article-title":"The methyltransferase G9a regulates HoxA9-dependent transcription in AML.","volume":"28","author":"Lehnertz","year":"2014","journal-title":"Genes Dev."},{"key":"B110","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/s0301-472x(03)00081-x","article-title":"Polycomb group genes as epigenetic regulators of normal and leukemic hemopoiesis.","volume":"31","author":"Lessard","year":"2003","journal-title":"Exp. Hematol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/nm.4125","article-title":"Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.","volume":"22","author":"Li","year":"2016","journal-title":"Nat. Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"292","DOI":"10.18632\/genesandcancer.117","article-title":"Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia.","volume":"7","author":"Li","year":"2016","journal-title":"Genes Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.celrep.2018.03.124","article-title":"SETDB2 links E2A-PBX1 to cell-cycle dysregulation in acute leukemia through CDKN2C repression.","volume":"23","author":"Lin","year":"2018","journal-title":"Cell Rep."},{"key":"B114","doi-asserted-by":"publisher","first-page":"8931","DOI":"10.1021\/jm401480r","article-title":"Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.","volume":"56","author":"Liu","year":"2013","journal-title":"J. Med. Chem."},{"key":"B115","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nrc3776","article-title":"Drug resistance: overcoming resistance in acute myeloid leukaemia treatment.","volume":"14","author":"Lokody","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","article-title":"Selective inhibition of tumor oncogenes by disruption of super-enhancers.","volume":"153","author":"Loven","year":"2013","journal-title":"Cell"},{"key":"B117","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/bmt.2009.222","article-title":"Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.","volume":"45","author":"Lubbert","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2018.1481813","article-title":"LSD1 inhibitors disrupt the GFI1 transcription repressor complex.","volume":"5","author":"Maiques-Diaz","year":"2018","journal-title":"Mol. Cell Oncol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2217\/epi-2016-2019","article-title":"LSD1: biologic roles and therapeutic targeting.","volume":"8","author":"Maiques-Diaz","year":"2016","journal-title":"Epigenomics"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1126\/science.1259037","article-title":"Oncogene regulation. an oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.","volume":"346","author":"Mansour","year":"2014","journal-title":"Science"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4469","article-title":"Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.","volume":"5","author":"Mar","year":"2014","journal-title":"Nat. Commun."},{"key":"B122","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1182\/blood-2017-03-775569","article-title":"SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.","volume":"130","author":"Mar","year":"2017","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The polycomb complex PRC2 and its mark in life.","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"B124","doi-asserted-by":"publisher","first-page":"6920","DOI":"10.1182\/blood-2011-08-368225","article-title":"ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN favorable genetic category.","volume":"118","author":"Metzeler","year":"2011","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1182\/blood-2014-04-571018","article-title":"Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)\/RUNX1-RUNX1T1 chromosomal translocations.","volume":"124","author":"Micol","year":"2014","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood-2005-06-2393","article-title":"Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis.","volume":"107","author":"Mihara","year":"2006","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/s1097-2765(02)00741-4","article-title":"MLL targets SET domain methyltransferase activity to Hox gene promoters.","volume":"10","author":"Milne","year":"2002","journal-title":"Mol. Cell."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1084\/jem.20160894","article-title":"Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.","volume":"214","author":"Moffitt","year":"2017","journal-title":"J. Exp. Med."},{"key":"B129","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ccr.2011.06.001","article-title":"Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.","volume":"20","author":"Moran-Crusio","year":"2011","journal-title":"Cancer Cell"},{"key":"B130","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.stem.2015.08.009","article-title":"Polycomb regulates mesoderm cell fate-specification in embryonic stem cells through activation and repression mechanisms.","volume":"17","author":"Morey","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B131","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"B132","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1172\/JCI69739","article-title":"Clinical development of demethylating agents in hematology.","volume":"124","author":"Navada","year":"2014","journal-title":"J. Clin. Invest."},{"key":"B133","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nm1161","article-title":"Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells.","volume":"11","author":"Nebbioso","year":"2005","journal-title":"Nat. Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1073\/pnas.1202258109","article-title":"Polycomb repressive complex 2 is required for MLL-AF9 leukemia.","volume":"109","author":"Neff","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B135","doi-asserted-by":"publisher","first-page":"6912","DOI":"10.1182\/blood-2011-02-334359","article-title":"DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.","volume":"117","author":"Nguyen","year":"2011","journal-title":"Blood"},{"key":"B136","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/ng.620","article-title":"Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.","volume":"42","author":"Nikoloski","year":"2010","journal-title":"Nat. Genet."},{"key":"B137","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cell.2005.02.020","article-title":"hDOT1L links histone methylation to leukemogenesis.","volume":"121","author":"Okada","year":"2005","journal-title":"Cell"},{"key":"B138","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia.","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B139","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3324\/haematol.2014.114157","article-title":"ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the german\u2014austrian acute myeloid leukemia study group.","volume":"100","author":"Paschka","year":"2015","journal-title":"Haematologica"},{"key":"B140","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1073\/pnas.0500369102","article-title":"Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.","volume":"102","author":"Peart","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B141","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/15592294.2016.1265710","article-title":"Bromodomain inhibitors and cancer therapy: from structures to applications.","volume":"12","author":"Perez-Salvia","year":"2017","journal-title":"Epigenetics"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020987","article-title":"Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells.","volume":"6","author":"Petruccelli","year":"2011","journal-title":"PLoS One"},{"key":"B143","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/eji.200838105","article-title":"DNA methylation controls Foxp3 gene expression.","volume":"38","author":"Polansky","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-231","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"B146","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ajh.22257","article-title":"Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies.","volume":"87","author":"Puda","year":"2012","journal-title":"Am. J. Hematol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B148","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nchembio.2304","article-title":"An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.","volume":"13","author":"Qi","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1182\/blood-2016-07-726877","article-title":"Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.","volume":"129","author":"Qu","year":"2017","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","article-title":"TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.","volume":"20","author":"Quivoron","year":"2011","journal-title":"Cancer Cell"},{"key":"B151","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1101\/gad.260174.115","article-title":"Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis.","volume":"29","author":"Rasmussen","year":"2015","journal-title":"Genes Dev."},{"key":"B152","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature14898","article-title":"Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.","volume":"525","author":"Rathert","year":"2015","journal-title":"Nature"},{"key":"B153","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/nm.4103","article-title":"A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells.","volume":"22","author":"Reinisch","year":"2016","journal-title":"Nat. Med."},{"key":"B154","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1182\/blood-2011-07-367961","article-title":"Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.","volume":"119","author":"Ribeiro","year":"2012","journal-title":"Blood"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1182\/blood-2009-03-209734","article-title":"Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis.","volume":"114","author":"Rizo","year":"2009","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1126\/science.1236062","article-title":"An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.","volume":"340","author":"Rohle","year":"2013","journal-title":"Science"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.leukres.2007.02.020","article-title":"Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis.","volume":"31","author":"Rohner","year":"2007","journal-title":"Leuk. Res."},{"key":"B158","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts.","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"B159","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/15592294.2016.1187350","article-title":"Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.","volume":"11","author":"Rucker","year":"2016","journal-title":"Epigenetics"},{"key":"B160","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","article-title":"Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting.","volume":"115","author":"Sanchez-Abarca","year":"2010","journal-title":"Blood"},{"key":"B161","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nm.2661","article-title":"Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia.","volume":"18","author":"Schenk","year":"2012","journal-title":"Nat. Med."},{"key":"B162","doi-asserted-by":"publisher","first-page":"6236","DOI":"10.1073\/pnas.91.13.6236","article-title":"ALL-1 partial duplication in acute leukemia.","volume":"91","author":"Schichman","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B163","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.3324\/haematol.2017.172411","article-title":"Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials.","volume":"103","author":"Schlenk","year":"2018","journal-title":"Haematologica"},{"key":"B164","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/leu.2012.262","article-title":"ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.","volume":"27","author":"Schnittger","year":"2013","journal-title":"Leukemia"},{"key":"B165","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"key":"B166","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2014\u2013a retrospective multicenter analysis from the german cooperative transplant study group.","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B167","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00277-017-3185-3185","article-title":"Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the german cooperative transplant study group.","volume":"97","author":"Schroeder","year":"2018","journal-title":"Ann. Hematol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1038\/sj.onc.1205436","article-title":"The leukemia-associated transcription repressor AML1\/MDS1\/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells.","volume":"21","author":"Senyuk","year":"2002","journal-title":"Oncogene"},{"key":"B169","doi-asserted-by":"publisher","first-page":"7886","DOI":"10.1128\/MCB.01547-1547","article-title":"Epigenetic control of the immune escape mechanisms in malignant carcinomas.","volume":"27","author":"Setiadi","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4161\/epi.23331","article-title":"G9a, a multipotent regulator of gene expression.","volume":"8","author":"Shankar","year":"2013","journal-title":"Epigenetics"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030815","article-title":"Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.","volume":"7","author":"Shen","year":"2012","journal-title":"PLoS One"},{"key":"B172","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade.","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"key":"B173","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/onc.2012.110","article-title":"The polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.","volume":"32","author":"Shi","year":"2013","journal-title":"Oncogene"},{"key":"B174","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.1182\/blood-2011-04-347476","article-title":"PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential.","volume":"119","author":"Shia","year":"2012","journal-title":"Blood"},{"key":"B175","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16508","article-title":"Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.","volume":"529","author":"Shu","year":"2016","journal-title":"Nature"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051029","article-title":"Roles of SETD2 in leukemia-transcription, DNA-damage, and beyond.","volume":"20","author":"Skucha","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.3324\/haematol.2018.199190","article-title":"Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes.","volume":"104","author":"Smitheman","year":"2019","journal-title":"Haematologica"},{"key":"B178","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1158\/0008-5472.CAN-06-4152","article-title":"Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.","volume":"67","author":"Stark","year":"2007","journal-title":"Cancer Res."},{"key":"B179","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"B180","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"B181","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"B182","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","article-title":"Emerging therapeutic drugs for AML.","volume":"127","author":"Stein","year":"2016","journal-title":"Blood"},{"key":"B183","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/bmt.2015.10","article-title":"5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft.","volume":"50","author":"Steinmann","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"B184","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ccell.2015.05.006","article-title":"Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy.","volume":"27","author":"Stratikopoulos","year":"2015","journal-title":"Cancer Cell"},{"key":"B185","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/leu.2017.59","article-title":"A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers.","volume":"31","author":"Sugino","year":"2017","journal-title":"Leukemia"},{"key":"B186","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1021\/ml400496h","article-title":"Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.","volume":"5","author":"Sweis","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"B187","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1084\/jem.20060750","article-title":"De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells.","volume":"204","author":"Tadokoro","year":"2007","journal-title":"J. Exp. Med."},{"key":"B188","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1182\/blood-2011-11-394932","article-title":"Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.","volume":"120","author":"Tanaka","year":"2012","journal-title":"Blood"},{"key":"B189","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1158\/2159-8290.CD-11-0181","article-title":"Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas.","volume":"1","author":"Taylor","year":"2011","journal-title":"Cancer Discov."},{"key":"B190","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.2011.35.4894","article-title":"Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.","volume":"29","author":"Thol","year":"","journal-title":"J. Clin. Oncol."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.3324\/haematol.2011.045559","article-title":"Rare occurrence of DNMT3A mutations in myelodysplastic syndromes.","volume":"96","author":"Thol","year":"","journal-title":"Haematologica"},{"key":"B192","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1182\/blood-2012-02-411686","article-title":"Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT.","volume":"119","author":"Toffalori","year":"2012","journal-title":"Blood"},{"key":"B193","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation.","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat. Med."},{"key":"B194","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nature20165","article-title":"S-2-hydroxyglutarate regulates CD8(+) T-lymphocyte fate.","volume":"540","author":"Tyrakis","year":"2016","journal-title":"Nature"},{"key":"B195","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of mismatched HLA in leukemia after stem-cell transplantation.","volume":"361","author":"Vago","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B196","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nchembio.599","article-title":"A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells.","volume":"7","author":"Vedadi","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"B197","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","article-title":"Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity.","volume":"23","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"key":"B198","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"key":"B199","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1126\/science.1060781","article-title":"Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor.","volume":"293","author":"Wang","year":"2001","journal-title":"Science"},{"key":"B200","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"B201","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 Blockade.","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B202","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-07-604512","article-title":"Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.","volume":"127","author":"Wouters","year":"2016","journal-title":"Blood"},{"key":"B203","doi-asserted-by":"publisher","first-page":"13141","DOI":"10.1074\/jbc.R700001200","article-title":"The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation.","volume":"282","author":"Wu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0043-49","article-title":"MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.","volume":"7","author":"Wyce","year":"2018","journal-title":"Oncogenesis"},{"key":"B205","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1182\/blood-2014-06-581082","article-title":"Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.","volume":"125","author":"Xu","year":"2015","journal-title":"Blood"},{"key":"B206","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00277-010-1128-1125","article-title":"Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.","volume":"90","author":"Xu","year":"2011","journal-title":"Ann. Hematol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"15540","DOI":"10.1073\/pnas.0607518103","article-title":"Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor.","volume":"103","author":"Xu","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B208","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"B209","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/1535-7163.MCT-12-0930","article-title":"Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.","volume":"12","author":"Yang","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"B210","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations.","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov."},{"key":"B211","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation.","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"key":"B212","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41422-018-0015-19","article-title":"Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation.","volume":"28","author":"Zhang","year":"2018","journal-title":"Cell Res."},{"key":"B213","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1101\/gad.1632608","article-title":"Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity.","volume":"22","author":"Zhao","year":"2008","journal-title":"Genes Dev."},{"key":"B214","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3324\/haematol.2018.187708","article-title":"Setd2 regulates quiescence and differentiation of adult hematopoietic stem cells by restricting RNA polymerase II elongation.","volume":"103","author":"Zhou","year":"2018","journal-title":"Haematologica"},{"key":"B215","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/ng.2894","article-title":"Identification of functional cooperative mutations of SETD2 in human acute leukemia.","volume":"46","author":"Zhu","year":"2014","journal-title":"Nat. Genet."},{"key":"B216","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"B217","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1073\/pnas.1317788111","article-title":"Cohesin and CTCF differentially affect chromatin architecture and gene expression in human cells.","volume":"111","author":"Zuin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2019.00207\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T03:49:39Z","timestamp":1570765779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2019.00207\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":217,"alternative-id":["10.3389\/fcell.2019.00207"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2019.00207","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]},"article-number":"207"}}